Nexavar

........................................................................................................................................................ 2 1 Chapter One: Introduction .......................................................................................................................... 6 1.1 Research background .......................................................................................................................... 6 1.2 Research questions .............................................................................................................................. 8 1.3 Justifications for the research .............................................................................................................. 8 1.4 Methodology ....................................................................................................................................... 9 1.5 Structure of thesis .............................................................................................................................. 10 2 Chapter Two: Compulsory License Overview: Focus on “Failure to Work” .......................................... 11 2.1 The Operation of the Compulsory License Regime .......................................................................... 11 2.1.1 Recognized grounds ....................................................................................................................... 12 2.2.1 Scope and duration ......................................................................................................................... 14 2.1.4 Remuneration ................................................................................................................................. 19 2.2 Compulsory License among other patent limitations ........................................................................ 20 3 Chapter Three: The Interface between Human Rights and Patent Law: The Correlation between Access to Medicines and “Failure to Work” ........................................................................................................... 23 3.1 The convergence of Access to Medicines and “Failure to Work” .................................................... 23 3.1.1 Subjugation .................................................................................................................................... 23 3.1.2 Integration ...................................................................................................................................... 24 3.1.3 Coexistence .................................................................................................................................... 26 3.2 The Content of Access to Medicines ................................................................................................. 28 3.2.1 Availability and Affordability ........................................................................................................ 30 4 Chapter four: The analyze of the Bayer Nexavar case ............................................................................ 32 4.1 Bayer in India .................................................................................................................................... 32 4.2. Before the Controller of Patents in Mumbai .................................................................................... 32 4.3 Before the Before the Intellectual Property Appellate Board ........................................................... 36 4.4 On the Ability of “Failure to Work” to Promotion Access to Medicines ......................................... 41 5 Chapter five: Conclusion .......................................................................................................................... 44 5.1 Conclusion and recommendations .................................................................................................... 44 6 Chapter six: Bibliography ........................................................................................................................ 45 6.1 Reference Table ................................................................................................................................ 45 

Sorafenib (Nexavar®, BAY 43-9006) is a novel multikinase inhibitor that has been recently approved for the treatment of advanced… Expand

Two separate clinical studies of advanced hepatocarcinoma patients recently reported that the multikinase inhibitor sorafenib… Expand

The majority of kinase inhibitors developed to date are competitive inhibitors that target the ATP binding site; however, recent… Expand

OBJECTIVE To study the therapeutic effects of Nexavar on liver cancer and its relation to the expressions of Ki-67 and CD34… Expand

Inhibition of receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptors (VEGFRs) and platelet-derived… Expand

Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral… Expand

Purpose:  To report on the effect of oral nexavar (Sorafenib®) treatment in one patient with neovascular age‐related macular… Expand

Sorafenib (NexavarⓇ) is an oral multikinase inhibitor that was recently approved for use in metastatic renal cancer. It is… Expand

Activating mutations in Ras and B-RAF were identified in several human cancers. In addition, several receptor tyrosine kinases… Expand